Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822637 · ClinicalTrials.gov registry record · Phase 4
The Effect of NAC on Lung Function and CT Mucus Score
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03822637: Clinical Trial Phase 4 study, sponsored by University of California, San Francisco.
NCT03822637 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03822637, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 14-day treatment period and placebo in the next 14-day treatment period; and the other half will get placebo in the first 14-day treatment period and 20% NAC in the next 14-day treatment period.
Primary Outcome
FEV1 Liters was assessed with participants in a seated position. FEV1 Liters was measured with a PC-based spirometer until at least 3 acceptable and 2 repeatable maneuvers were captured. The highest maneuver was recorded. The percent change in mean FEV1 Liters from baseline to 2 weeks after treatment was calculated.
Interventions
- COMBINATION_PRODUCT n-acetylcystine + albuterol
- COMBINATION_PRODUCT 0.9% saline + albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-02-20 |
| Est. Completion | 2025-02-21 |
| Phase | Phase 4 |
Why NCT03822637 stopped before completion
NCT03822637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which n-acetylcystine + albuterol is the first listed.
NCT03822637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03822637 about?
NCT03822637 is a clinical study titled "The Effect of NAC on Lung Function and CT Mucus Score". This study evaluates 20% n-acetylcysteine (NAC) in the treatment of moderate-to-severe asthma that is complicated by mucus in the airway, as determined by CT imaging. The study is a crossover design, which means that half the study participants will get 20% NAC in the first 14-day treatment period a...
What is the current status of trial NCT03822637?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2019-02-20. Estimated completion is 2025-02-21.
What interventions are being tested in trial NCT03822637?
The interventions under investigation include: n-acetylcystine + albuterol (COMBINATION_PRODUCT), 0.9% saline + albuterol (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03822637?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03822637's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI